ABIONYX Pharma Announces Landmark Validation: A Study Published in NATURE Confirms Genetic Causality of Apolipoprotein A-I (ApoA-I) in Sepsis

Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only ...

Lupus Foundation of America Research Showcased at 2025 American College of Rheumatology Annual Meeting

The Lupus Foundation of America (LFA) and its funded researchers will unveil the latest advances in patient-centered research ...

Danaher Corporation (DHR) Q3 2025 Earnings Call Transcript

Danaher Corporation ( NYSE: DHR) Q3 2025 Earnings Call October 21, 2025 8:00 AM EDT ...
PharmiWeb

Subcutaneous RYBREVANT® (amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and ...

Responses were rapid and durable, and tumour shrinkage was observed in 82 percent of patients[i] New findings from this investigational study build on the strength of the data for amivantamab in ...